Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Toronto

$852,975.00

198Au-Nanodepot Combined with Adjuvant Auger Electron Radioimmunotherapy, Immunotherapy and Chemotherapy for Triple-Negative Breast Cancer in Metastatic Humanized Mouse Models

FY 2024-25

Summary
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that has a high risk of recurrence and spread to distant organs (metastasis) even if detected at an early stage. We propose to study a new radiation treatment for early stage TNBC in mice with human TNBC tumours that could more effectively treat these tumours and prevent metastasis. These mice are a special strain that displays a human immune system so that the ability of this new treatment to recruit the immune system to attack tumours may be studied. One component of the new treatment will be a small "seed" (nanoparticle depot) that can be implanted into a tumour to locally treat the tumour with radiation. The mice will also be treated with immunotherapy and chemotherapy, which are the standard treatments for early stage TNBC. Following local treatment of the TNBC tumour with the nanoparticle depot, the mice will then receive an intravenously administered form of radiation treatment (radioimmunotherapy) that can target and kill tumour cells that have spread throughout the body. This treatment will also be combined with immunotherapy. The goal is to more effectively treat TNBC tumours and prevent or treat metastasis since metastatic TNBC is not curable leading unfortunately to death from this aggressive form of breast cancer.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
508568
Name
Reilly Raymond M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
198Au-Nanodepot Combined with Adjuvant Auger Electron Radioimmunotherapy, Immunotherapy and Chemotherapy for Triple-Negative Breast Cancer in Metastatic Humanized Mouse Models
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$852,975
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
111in; 198au; Auger Electrons; Brachytherapy; Epidermal Growth Factor Receptor (Egfr); Humanized Mice; Immunotherapy; Radiation Nanomedicine; Radioimmunotherapy; Triple-Negative Breast Cancer
Abstract
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that has a high risk of recurrence and spread to distant organs (metastasis) even if detected at an early stage. We propose to study a new radiation treatment for early stage TNBC in mice with human TNBC tumours that could more effectively treat these tumours and prevent metastasis. These mice are a special strain that displays a human immune system so that the ability of this new treatment to recruit the immune system to attack tumours may be studied. One component of the new treatment will be a small "seed" (nanoparticle depot) that can be implanted into a tumour to locally treat the tumour with radiation. The mice will also be treated with immunotherapy and chemotherapy, which are the standard treatments for early stage TNBC. Following local treatment of the TNBC tumour with the nanoparticle depot, the mice will then receive an intravenously administered form of radiation treatment (radioimmunotherapy) that can target and kill tumour cells that have spread throughout the body. This treatment will also be combined with immunotherapy. The goal is to more effectively treat TNBC tumours and prevent or treat metastasis since metastatic TNBC is not curable leading unfortunately to death from this aggressive form of breast cancer.
Competitiondate
202409
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Reilly, Raymond M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $852,975~ $0~
University of Toronto - $852,975 Grant (2024-25) | Canada Spends